Eurobio Scientific profit nearly doubles as CareDx acquisition precedes €25.30 take-private offer

Eurobio Scientific reported a sharp improvement in first-half profitability as the French diagnostics group continued shifting toward proprietary products and international markets, while a newly completed acquisition is set to materially expand the business during the second half. Revenue increased 4.5% to €84.5 million, EBITDA rose 20% to €15.8 million and net income nearly doubled to €4.7 million from €2.4 million. Proprietary products generated €31.3 million and increased 10%, lifting their share of total revenue to approximately 37%, while 46% of group revenue came from outside France. The results arrive as Eurobio Scientific begins integrating the Lab Solutions business acquired from CareDx and prepares for a proposed €25.30-per-share public buyout followed by a mandatory squeeze-out of remaining minority shareholders.

The combination creates an unusual investment story because operational transformation and ownership transformation are occurring simultaneously. Eurobio Scientific is becoming larger, more international and more heavily exposed to proprietary transplant diagnostics, but public investors may have limited time to participate in that next phase if majority shareholder EB Development completes its planned delisting. EB Development now owns 90.14% of Eurobio Scientific and has formally filed a proposed public buyout with French market authorities, with minority shareholders expected to receive the same €25.30-per-share consideration if the subsequent squeeze-out proceeds.

Proprietary products and international expansion improve Eurobio Scientific’s earnings mix

Eurobio Scientific’s first-half revenue increased by €3.6 million from €80.8 million a year earlier, but acquisition effects remained an important contributor. On a comparable pro forma basis excluding changes in consolidation scope, revenue was essentially flat, showing that the reported growth did not come entirely from organic expansion.

The strongest underlying improvement came from proprietary products. Revenue from products developed or owned by Eurobio Scientific increased 10% to €31.3 million, while organic growth excluding acquisition effects was approximately 7%. Proprietary products now represent about 37% of total revenue compared with 36% previously.

That mix matters because proprietary diagnostics generally offer greater control over intellectual property, pricing and distribution than third-party products. Eurobio Scientific has been deliberately increasing this part of the portfolio through internal development and acquisitions, particularly in transplantation, infectious diseases, oncology and quality-control applications.

The GenDx transplantation business contributed to the increase, alongside infectious-disease and quality-control products. Revenue from distributed products was €53.2 million, up 2% on a reported basis but down 5% excluding changes in scope, partly because Eurobio Scientific no longer benefited from certain tenders involving One Lambda products.

International expansion is following a similar pattern. Revenue outside France reached €39.1 million, representing 46% of the group total compared with 41% a year earlier, as acquisitions and existing operations in Europe, the United States and Australia expanded the geographic mix.

The progression continues a multi-year strategic shift. Fiscal 2025 revenue increased 9% to €168.3 million, while proprietary products reached 35% of revenue and international markets represented 42%. The latest half-year figures show both measures continuing to rise, even though comparable overall revenue growth has become more subdued.

CareDx Lab Solutions deal could materially increase Eurobio Scientific’s scale

The most important future growth driver did not contribute anything to first-half revenue. Eurobio Scientific completed its acquisition of CareDx’s Lab Solutions business on June 30, meaning the acquired operations were included on the balance sheet but contributed no sales or earnings to the reported six-month period.

CareDx received $171.2 million in cash at closing, subject to customary adjustments. The transaction transferred a portfolio of laboratory diagnostic products focused primarily on transplantation, including AlloSeq, QTYPE and associated software and technologies used for HLA typing and chimerism monitoring.

The acquired business produced approximately $13 million of revenue during CareDx’s second quarter, up from $12 million a year earlier. That quarter represented a full period of ownership by CareDx before the sale closed, providing an indication of the scale that could begin contributing to Eurobio Scientific during the second half.

Strategically, the deal deepens Eurobio Scientific’s position in transplant diagnostics, where it already owns GenDx. Combining GenDx with CareDx’s Lab Solutions portfolio gives the company a broader selection of molecular products across donor typing, recipient typing and monitoring applications, while adding commercial reach in markets where Eurobio historically had less scale.

The acquisition also significantly increases Eurobio Scientific’s exposure outside France. CareDx operated Lab Solutions internationally, and Eurobio Scientific specifically identified the transaction as a way to strengthen its international transplant diagnostics position.

The deal is therefore more than a bolt-on transaction. At roughly $171 million of cash consideration, it is comparable in size to an entire year of Eurobio Scientific’s existing revenue and represents one of the most consequential steps in the group’s shift from a French diagnostics distributor toward a multinational proprietary-products platform.

EBITDA rises 20% as operating efficiency improves faster than revenue

Eurobio Scientific’s earnings increased considerably faster than sales. EBITDA rose to €15.8 million from €13.2 million, while operating income before certain intangible amortization effects increased 45% to €8.5 million from €5.8 million. Net income almost doubled to €4.7 million.

Gross margin improved slightly to 47.5% from 47.3%, helped by the growing contribution from proprietary products. Cost control provided a larger benefit, with overall operating expenses declining 1.3% despite revenue growth.

Sales and marketing expenses dropped 8% to €16.6 million following restructuring of the EndoPredict and Prolaris oncology sales activities, while general and administrative expenses increased 9% to €8.4 million. Research and development spending rose modestly to €2.4 million from €2.2 million.

The improvement shows why product mix matters to Eurobio Scientific’s strategy. A larger share of proprietary products combined with tighter commercial spending can allow earnings to grow faster than revenue, even when underlying market growth remains moderate.

Free cash flow before acquisitions reached approximately €4 million after €7.5 million of operating cash generation and €3.5 million of net capital spending. Working capital absorbed €5 million, preventing a larger cash-flow increase despite stronger profitability.

CareDx financing pushes reported net debt sharply higher

The acquisition had a much larger effect on Eurobio Scientific’s balance sheet than on its first-half income statement. The company reported net debt of €147.4 million when financing received from controlling shareholder EB Development is included.

That headline requires context. Eurobio Scientific held €26.3 million of cash and approximately €15 million of conventional loans, financial debt and leases, leaving it with positive net cash before the EB Development funding. The apparent increase in leverage primarily reflects €164.7 million owed through EB Development’s current account, including €154.4 million advanced to finance the CareDx transaction.

The shareholder financing allowed Eurobio Scientific to complete the acquisition without immediately relying on conventional external borrowing for the entire purchase price. It also demonstrates the increasingly close relationship between the operating company and the investor group that now intends to remove Eurobio Scientific from the public market.

The acquisition creates an additional earnings burden through financing costs, although first-half net financial expense actually improved to €1.2 million from €2.1 million. The larger CareDx financing was only put in place at the end of the reporting period, meaning its full effect will become more visible in future results.

Management does not publish annual financial guidance, leaving investors without a formal revenue or EBITDA target for the combined company. The second half will therefore provide the first evidence of how the CareDx assets affect consolidated sales, margins, cash generation and financing costs.

Seegene transition creates an important revenue challenge for 2027

Eurobio Scientific’s acquisition strategy is partly offsetting a potentially significant change in its distribution business. South Korean diagnostics company Seegene plans to enter the French market directly from January 1, 2027, ending a distribution relationship that has existed since 2011.

The contract is financially important. Seegene products generated approximately €48 million of Eurobio Scientific revenue during fiscal 2025 and another €25.6 million during the first half, representing 12% growth from the comparable period.

Eurobio Scientific will be allowed, with Seegene’s consent, to continue fulfilling certain existing private contracts for as long as three years and public tenders for their awarded duration. The change therefore does not necessarily remove all associated revenue immediately, but it creates a significant transition risk beginning in 2027.

That development makes the timing of the CareDx acquisition especially important. Expanding proprietary transplant products and international revenue can reduce the company’s dependence on large third-party distribution relationships as Seegene gradually moves toward direct sales.

The broader strategy becomes clearer when these developments are considered together. Eurobio Scientific is using acquisitions to replace a distribution-heavy model with a larger proprietary-product portfolio, giving the company more control over future revenue streams but requiring significantly more capital and integration work.

€25.30 buyout could remove Eurobio Scientific from public markets during its next growth phase

EB Development has formally filed a public buyout offer at €25.30 per share, followed by a proposed mandatory squeeze-out. The shareholder directly controls 90.14% of Eurobio Scientific after the cancellation of treasury shares, leaving less than 10% of the company in minority hands.

The €25.30 offer represents a 24.02% premium to Eurobio Scientific’s closing share price immediately before the planned offer was announced. It also represents premiums of 22.71% and 16.05% to the 60-day and 120-day volume-weighted average prices, respectively.

The market largely adjusted toward the proposed price after the announcement, with shares recently trading around €25.20. That leaves only a small spread to the offer price and suggests investors currently assign a high probability to completion, although the process remains subject to review by France’s Autorité des Marchés Financiers.

Independent expert Ledouble has been appointed to assess the financial terms and prepare a fairness opinion. If the offer proceeds and minority ownership remains below the applicable threshold, EB Development intends to implement the mandatory squeeze-out at the same €25.30 price.

EB Development argues that leaving Euronext Growth Paris would reduce costs associated with maintaining a public listing. The ownership structure also includes investment funds managed by IK Partners, NextStage and members of Eurobio Scientific’s management and board, including Chief Executive Officer Denis Fortier.

The timing means minority shareholders may exit just as the CareDx acquisition starts contributing to consolidated results. Whether €25.30 fully captures the future value of the expanded diagnostics platform is therefore central to the independent valuation process, rather than something that can be determined solely from the latest half-year earnings.

Key takeaways from Eurobio Scientific’s profit growth, CareDx acquisition and €25.30 buyout

• First-half revenue increased 4.5% to €84.5 million, while EBITDA rose 20% to €15.8 million.
• Net income nearly doubled to €4.7 million from €2.4 million as operating efficiency improved.
• Proprietary-product revenue increased 10% to €31.3 million and now represents about 37% of group sales.
• International revenue reached €39.1 million, increasing its contribution to 46% of total revenue.
• Eurobio Scientific completed the acquisition of CareDx’s Lab Solutions business for approximately $171 million in cash.
• The CareDx assets contributed no first-half revenue because the acquisition closed at the end of the reporting period.
• EB Development provided €154.4 million of financing specifically related to the CareDx transaction, driving reported net debt higher.
• Seegene plans to begin selling directly in France in 2027, creating a meaningful transition risk for a relationship that generated €48 million of 2025 revenue.
• EB Development now owns 90.14% of Eurobio Scientific and has filed a €25.30-per-share public buyout offer.
• A mandatory squeeze-out is planned after the offer, potentially ending Eurobio Scientific’s public listing as its expanded transplant diagnostics platform begins contributing.